6IZN
Crystal structure of the PPARgamma-LBD complexed with compound 3g
Summary for 6IZN
Entry DOI | 10.2210/pdb6izn/pdb |
Descriptor | Peroxisome proliferator-activated receptor gamma, Peptide from Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-7-fluoranyl-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid, ... (4 entities in total) |
Functional Keywords | transcription |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 2 |
Total formula weight | 34901.38 |
Authors | Matsui, Y.,Hanzawa, H. (deposition date: 2018-12-20, release date: 2019-03-27, Last modification date: 2023-11-22) |
Primary citation | Shinozuka, T.,Tsukada, T.,Fujii, K.,Tokumaru, E.,Matsui, Y.,Wakimoto, S.,Ogata, T.,Araki, K.,Sawamura, R.,Watanabe, N.,Mori, M.,Tanaka, J. Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930. Acs Med.Chem.Lett., 10:358-362, 2019 Cited by PubMed Abstract: Derivatization efforts were continued to discover backups for a potent selective PPARγ modulator, DS-6930. In this Letter, the replacement of 2-pyridine ring in DS-6930 with 3- or 4-pyridyl group is reported. As the introduction of substituents on the pyridine ring did not provide potent partial agonists, modifications of benzimidazole ring were explored to discover potent intermediate agonists. 4'-Alkoxy substituted benzimidazoles failed to show potent efficacy in vivo, whereas 7'-fluoro benzimidazole (DS19161384) was found to result in robust plasma glucose reductions with excellent DMPK profiles. PubMed: 30891140DOI: 10.1021/acsmedchemlett.8b00645 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.75 Å) |
Structure validation
Download full validation report
